Meneldor
VC Fund
Druten, The Netherlands
Meneldor is a biopharmaceutical investment company .
- Total investments:
- 7
- Last investment:
- Lead investor:
- 86%
Last updated:
For AI agents: llms.txt
Industries Meneldor invests in
Stages Meneldor invests in
Countries Meneldor invests in
Round sizes
Contacts
| Name | Phone | Socials | |
|---|---|---|---|
4 more contacts available
Round size
- Series A
- $2.2M–$65M
Investment Focus
Industry
- Biotechnology 4 (57%)
- Health Care 3 (43%)
- Pharmaceutical 2 (29%)
- Health Diagnostics 2 (29%)
- Medical 1 (14%)
Stage
- Series A 4 (57%)
- Seed 1 (14%)
- Debt Financing 1 (14%)
Country
- Norway 1 (14%)
- Germany 1 (14%)
- United Kingdom 1 (14%)
- The Netherlands 1 (14%)
Team
| Name | Title | Investments | Links | |
|---|---|---|---|---|
Paul Lelieveld
Founding Partner
|
Founding Partner | Total investments: 5 | Find email |
Investments
| Company | Description | Round | Links |
|---|---|---|---|
Tagworks Pharmaceuticals
|
Tagworks Pharmaceuticals is a privately held biotech company based in the Netherlands. Tagworks develops In vivo chemistry to improve the efficacy of cancer therapies and to enable novel approaches in companion diagnostics. The company’s facilities are located at the Radboud University Medical Center in Nijmegen. Founded in 2011, Tagworks is aspin-out of Philips Healthcare, and originates from Philips’ molecular imaging expertise. | $65M / Series A / Jun 22, 2023 | |
Hemispherian
|
Hemispherian is a biotechnology firm that formulates new treatments for all kinds of cancer. | $3M / Series A / Nov 24, 2022 | |
|
Hemispherian
|
Hemispherian is a biotechnology firm that formulates new treatments for all kinds of cancer. | $1.3M / Seed / May 03, 2022 | |
Atriva Therapeutics
|
Atriva Therapeutics is a biopharmaceutical company which aims to develop new antiviral therapies against different respiratory viral infections. Atriva Therapeutics completed preclinical development of ATR-002 and recently filed a request for scientific advice from a European regulatory authority to provide guidance on the executed preclinicaldevelopment program and the planned ATR-002 Phase I study in healthy volunteers. | $10.1M / Debt Financing / Aug 12, 2020 | |
|
Atriva Therapeutics
|
Atriva Therapeutics is a biopharmaceutical company which aims to develop new antiviral therapies against different respiratory viral infections. Atriva Therapeutics completed preclinical development of ATR-002 and recently filed a request for scientific advice from a European regulatory authority to provide guidance on the executed preclinicaldevelopment program and the planned ATR-002 Phase I study in healthy volunteers. | $10.1M / Debt Financing / Aug 12, 2020 | |
|
Atriva Therapeutics
|
Atriva Therapeutics is a biopharmaceutical company which aims to develop new antiviral therapies against different respiratory viral infections. Atriva Therapeutics completed preclinical development of ATR-002 and recently filed a request for scientific advice from a European regulatory authority to provide guidance on the executed preclinicaldevelopment program and the planned ATR-002 Phase I study in healthy volunteers. | Series A / Jan 03, 2019 | |
Aptamer Group
|
The Aptamer group of companies focuses on the development of aptamer technologies. We develop nucleic acid aptamers for use in research & development, biomarker discovery, diagnostics or therapeutic developments. Aptamers are short DNA or RNA sequences that offer high-affinity and specificity to virtually all types of targets. They cantherefore be thought of as synthetic nucleic acid equivalents of antibodies. Aptamers are versatile, cost effective and offer a complementary or alternative solution to antibodies. We have over 20 years combined expertise in the development of nucleic acid aptamers to peptides, proteins, cells, tissue samples, micro-organisms and small molecules.The Aptamer Group of companies has cutting edge platforms for the selection of aptamers. These include semi-automated selection platforms which ensure accurate replication of selection conditions to ensure the best quality aptamers result. We can use a wide range of targets: peptide, proteins, whole cells, viruses, small molecules etc. The typical aptamer selection process can be completed in a matter of weeks. Monoclonal antibodies usually take several months to generate.Our custom service can be focussed on a particular application so that the resultant aptamers are pre-optimized for use with a given detection platform, sample type and assay buffer. Aptamers themselves are increasingly being perceived as the state of the art reagent of choice for a wide range of applications including:Imaging experiments: fluorescence, bright field and phase contrast, IHC, ICC Quantification: ELISA (or ELONA), homogeneous assays etc. Rapid diagnostics: Lateral flow devices, biosensors, electrochemical detection, nano-wires Binding studies: label free detection, SPR, Biolayer Interferometry Purification: affinity chromatography We also offer an aptamer based assay development service. Our solution can be used to identify aptamers for virtually any application and against almost any target in almost any condition. Our applications are more diverse than those for which antibodies have been used. These include therapeutics, in biomarker discover, in drug target discovery, as diagnostics, in biosensors as components of biochemical tests such as Lateral flow devices, enzyme linked oligonucleotide assays (ELONA: the aptamer based equivalent of ELISA), in affinity chromatography and as research reagents.For more information visit: www.aptamergroup.com | $2.2M / Series A / Jun 29, 2018 |
Co-Investors
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar industry
Similar stage
Similar country
Featured in Investor Lists
Recommended lists
FAQ
What does Meneldor invest in?
Meneldor invests primarily in Biotechnology, Health Care and Pharmaceutical startups, most often at Series A and Seed stage. Most of the 7 investments tracked by Shizune back companies in Norway. The Investment Focus section breaks down every industry, stage and country in the portfolio.
What is Meneldor's check size?
Meneldor typically joins rounds of $2.2M–$65M at Series A. These ranges are 10th–90th percentile round sizes calculated from confirmed public funding rounds, so they are a realistic guide to the rounds Meneldor participates in.
How do I contact Meneldor?
Public channels for Meneldor include LinkedIn and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
Who are the partners at Meneldor?
The team at Meneldor includes Paul Lelieveld (Founding Partner). The Team section lists each member with their title, investment count and links.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
